Nathan Wei

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Roy Fleischmann, Eduardo Mysler, Stephen Hall et al. · The Lancet · 2017 · 496 citations

Medicine, Pharmacology, Pharmacotherapy +12

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

D L Boyle, K. Soma, J Hodge et al. · Annals of the Rheumatic Diseases · 2014 · 298 citations · Full text

Medicine, Pathobiology, Pharmacology +17

Efficacy and Safety of CE-224,535, an Antagonist of P2X₇Receptor, in Treatment of Patients with Rheumatoid Arthritis Inadequately Controlled by Methotrexate

Thomas Stock, Bradley J. Bloom, Nathan Wei et al. · The Journal of Rheumatology · 2012 · 238 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results

Arthur Kavanaugh, Sanna Rosengren, Sang Jin Lee et al. · Annals of the Rheumatic Diseases · 2007 · 179 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial

Richard Radnovich, David F. Scott, A.T. Patel et al. · Osteoarthritis and Cartilage · 2017 · 144 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +17